Reserchers

JO Michiko Assistant Professor

JO Michiko

AffiliationLaboratory of Drug Discovery and Development for Pre-disease, Division of Presymptomatic Disease, Department of Research and Development

Research fieldsKampo medicines ・pharmacology

Campus careerPh.D.

Biography Academic Research Staff

Education

2001. 3. B.S. Faculty of Pharmaceutical Sciences, Tokushima Bunri University
2006. 3. Ph. D Graduate School of Pharmaceutical Sciences, Toyama University
2006. 3. Ph. D Graduate School of Pharmaceutical Sciences, Toyama University

Job career

2006. 4. Endowed Research Faculty Member, Division of Kampo Diagnostics, Department of Clinical Science, Institute of Natural Medicine, University of Toyama
2010. 4. Assistant Professor, Division of Kampo Diagnostics, Department of Clinical Science, Institute of Natural Medicine, University of Toyama

Research theme

Department

Division

Section

Project

Outline of the research

The best medicine is that of treatments of the pre-disease state; this is known as mibyou in traditional Japanese medicine. The concept was first explained in the Yellow Emperor’s Inner Canon, the oldest surviving book on Chinese medicine. Recently, many exceptionally effective but expensive pharmaceuticals, such as antibody drugs and molecular-targeted agents, have been developed, and these contribute our health and welfare. However, the increasing burden of treatments using these drugs will surely lead to medical economic disaster. With this in mind, the goal of my study is to clear the biological mechanisms of the pre-disease state and create new preemptive medicines targeting the pre-disease state. I mainly plan to do this using research techniques related to pharmaceutical science, immunology, pharmacology, and traditional medicine.

Thoughts on research

It is important to take precautions before developing some diseases without effective treatment, for example preemptive medicine and development of diagnostic agent. I aim to find to what extent the glutaminase inhibitor may prevent the onset of disease.
Most of my studies have been aimed to clarify the molecular and cellular mechanisms of Kampo medicines, with the goal of helping patients with edema. Furthermore, I have expanded my focus to explore the developing novel application of glutaminase inhibitor and new drug treatment, and I try to establish the research lead to identify of novel biomarkers for studying characterization of pre-disease state.

Paper

Jo M, Trujillo AN, Yang Y, Breslin JW.:Evidence of functional ryanodine receptors in rat mesenteric collecting lymphatic vessels. Am J Physiol Heart Circ Physiol.,
1;317(3):561-574, 2019

keyword

pre-disease signals, glutaminase Inhibitor, lymphatic vessel, Kampo